Shire has made available Intuniv (guanfacine extended-release tablets), a selective alpha-2A adrenergic receptor agonist, for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents 6–17 years of age.

Intuniv is not a controlled substance and has no known potential for abuse or dependence. Intuniv is available in 1mg, 2mg, 3mg, and 4mg dosage strengths.

For more information call (800) 536-7878 or visit